{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T19:39:02Z","timestamp":1774121942900,"version":"3.50.1"},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>From 1993 to 2010, annual U.S. tuberculosis (TB) rates declined by 58%. However, this decline has slowed and disproportionately occurred among U.S.-born (78%) versus foreign-born persons (47%). Addressing the high burden of latent TB infection (LTBI) must be prioritized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Only Tennessee has implemented a statewide program for finding and treating people with LTBI. The program was designed to address high statewide TB rates and growing burden among the foreign-born. We sought to assess the feasibility and yield of Tennessee\u2019s program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Analyzing data from the 4.8-year period from program inception in March 2002 through December 2006, we quantified patients screened using a TB risk assessment tool, tuberculin skin tests (TST) placed and read, TST results, and patients initiating and completing LTBI treatment. We then estimated the number needed to screen to find and treat one person with LTBI and to prevent one case of TB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Of 168,517 persons screened, 102,709 had a TST placed and read. Among 9,090 (9%) with a positive TST result, 53% initiated treatment, 54% of whom completed treatment. An estimated 195 TB cases were prevented over the 4.8 years analyzed, and program performance measures improved annually. The number of TSTs placed to prevent one TB case ranged from 150 for foreign-born persons to 9,834 for persons without TB risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Targeted tuberculin testing and LTBI treatment is feasible and likely to reduce TB rates over time. Yield and cost-effectiveness are maximized by prioritizing foreign-born persons, a large population with high TB risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201111-2076oc","type":"journal-article","created":{"date-parts":[[2012,5,5]],"date-time":"2012-05-05T05:04:34Z","timestamp":1336194274000},"page":"273-279","source":"Crossref","is-referenced-by-count":22,"title":["Moving toward Tuberculosis Elimination: Implementation of Statewide Targeted Tuberculin Testing in Tennessee"],"prefix":"10.1093","volume":"186","author":[{"given":"Kevin P.","family":"Cain","sequence":"first","affiliation":[{"name":"Division of Tuberculosis Elimination and"},{"name":"Epidemic Intelligence Service, Office of Workforce and Career Development, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie N.","family":"Garman","sequence":"additional","affiliation":[{"name":"Communicable and Environmental Diseases Section, Tennessee Department of Health, Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayla F.","family":"Laserson","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Odile P.","family":"Ferrousier-Davis","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination and"},{"name":"The International Union Against TB and Lung Disease (The Union), Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham G.","family":"Miranda","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination and"},{"name":"Office of Global Affairs\/Office of the Secretary, U.S. Department of Health and Human Services, Brasilia, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles D.","family":"Wells","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination and"},{"name":"Otsuka Pharmaceutical Development & Commercialization, Rockville, Maryland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Connie A.","family":"Haley","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination and"},{"name":"Communicable and Environmental Diseases Section, Tennessee Department of Health, Nashville, Tennessee"},{"name":"Vanderbilt University, Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2012,8,1]]},"reference":[{"key":"2026032101000126500_bib1","article-title":"Reported tuberculosis in the United States, 2010","author":"Centers for Disease Control and Prevention","year":"2011"},{"key":"2026032101000126500_bib2","first-page":"333","article-title":"Trends in tuberculosis\u2013United States, 2010","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026032101000126500_bib3","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1164\/ajrccm.158.6.9804029","article-title":"Differences in contributing factors to tuberculosis incidence in US-born and foreign-born persons","volume":"158","author":"Chin","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101000126500_bib4","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa012972","article-title":"Changes in the transmission of tuberculosis in New York City from 1990 to 1999","volume":"346","author":"Geng","year":"2002","journal-title":"N Engl J Med"},{"key":"2026032101000126500_bib5","doi-asserted-by":"crossref","first-page":"971","DOI":"10.7326\/0003-4819-130-12-199906150-00004","article-title":"A molecular epidemiologic analysis of tuberculosis trends in San Francisco, 1991\u20131997","volume":"130","author":"Jasmer","year":"1999","journal-title":"Ann Intern Med"},{"key":"2026032101000126500_bib6","doi-asserted-by":"crossref","first-page":"e27405","DOI":"10.1371\/journal.pone.0027405","article-title":"Estimating the burden of tuberculosis among foreign-born persons acquired prior to entering the US, 2005\u20132009","volume":"6","author":"Ricks","year":"2011","journal-title":"PLoS ONE"},{"key":"2026032101000126500_bib7","first-page":"1","article-title":"American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"49","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"2026032101000126500_bib8"},{"key":"2026032101000126500_bib9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1164\/rccm.200608-1178OC","article-title":"Tuberculosis among foreign-born persons in the United States: achieving tuberculosis elimination","volume":"175","author":"Cain","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101000126500_bib10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1086\/523732","article-title":"Editorial commentary: overcoming the limits of tuberculosis prevention among foreign-born individuals: next steps toward eliminating tuberculosis","volume":"46","author":"Cain","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2026032101000126500_bib11","first-page":"1","article-title":"Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America","volume":"54","author":"Taylor","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"2026032101000126500_bib12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1164\/rccm.200303-390OC","article-title":"Use of isoniazid for latent tuberculosis infection in a public health clinic","volume":"168","author":"LoBue","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101000126500_bib13","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1001\/jama.281.11.1014","article-title":"Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic","volume":"281","author":"Nolan","year":"1999","journal-title":"JAMA"},{"key":"2026032101000126500_bib14","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S1473-3099(11)70102-5","article-title":"Is screening immigrants for latent tuberculosis cost-effective?","volume":"11","author":"Mandalakas","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"2026032101000126500_bib15","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1473-3099(11)70069-X","article-title":"Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis","volume":"11","author":"Pareek","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"2026032101000126500_bib16","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1056\/NEJMsa021099","article-title":"Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States","volume":"347","author":"Khan","year":"2002","journal-title":"N Engl J Med"},{"key":"2026032101000126500_bib17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0749-3797(18)31204-2","article-title":"Tuberculosis prevention: cost-effectiveness analysis of isoniazid chemoprophylaxis","volume":"4","author":"Rose","year":"1988","journal-title":"Am J Prev Med"},{"key":"2026032101000126500_bib18","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1001\/jama.1986.03380190079029","article-title":"The age threshold for isoniazid chemoprophylaxis. A decision analysis for low-risk tuberculin reactors","volume":"256","author":"Rose","year":"1986","journal-title":"JAMA"},{"key":"2026032101000126500_bib19","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.7326\/0003-4819-127-12-199712150-00001","article-title":"Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis","volume":"127","author":"Salpeter","year":"1997","journal-title":"Ann Intern Med"},{"key":"2026032101000126500_bib20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0749-3797(18)31022-5","article-title":"Tuberculin screening: cost-effectiveness analysis of various testing schedules","volume":"6","author":"Schechter","year":"1990","journal-title":"Am J Prev Med"},{"key":"2026032101000126500_bib21","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1001\/jama.1986.03370120057023","article-title":"Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy","volume":"255","author":"Snider","year":"1986","journal-title":"JAMA"},{"key":"2026032101000126500_bib22","first-page":"1","article-title":"Tuberculosis elimination revisited: obstacles, opportunities, and a renewed commitment","volume":"48","author":"Advisory Council for the Elimination of Tuberculosis (ACET)","year":"1999","journal-title":"MMWR Recomm Rep"},{"key":"2026032101000126500_bib23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jama.300.4.405","article-title":"Tuberculosis among foreign-born persons in the United States","volume":"300","author":"Cain","year":"2008","journal-title":"JAMA"},{"key":"2026032101000126500_bib24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/003335490612100202","article-title":"Improved program activities are associated with decreasing tuberculosis incidence in the United States","volume":"121","author":"Lobato","year":"2006","journal-title":"Public Health Rep"},{"key":"2026032101000126500_bib25","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1164\/rccm.200510-1563OC","article-title":"The scope and impact of treatment of latent tuberculosis infection in the United States and Canada","volume":"173","author":"Sterling","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101000126500_bib26","article-title":"Treatment of latent tuberculosis infection","author":"Haley","year":"2011","edition":"6th ed"},{"key":"2026032101000126500_bib27","first-page":"1235","article-title":"Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada","volume":"12","author":"Hirsch-Moverman","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026032101000126500_bib28","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1056\/NEJMsa031667","article-title":"Priorities for the treatment of latent tuberculosis infection in the United States","volume":"350","author":"Horsburgh","year":"2004","journal-title":"N Engl J Med"},{"key":"2026032101000126500_bib29","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1378\/chest.09-0394","article-title":"Latent TB infection treatment acceptance and completion in the United States and Canada","volume":"137","author":"Horsburgh","year":"2010","journal-title":"Chest"},{"key":"2026032101000126500_bib30","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1440-1843.2010.01751.x","article-title":"Treatment of latent tuberculosis infection: an update","volume":"15","author":"LoBue","year":"2010","journal-title":"Respirology"},{"key":"2026032101000126500_bib31","article-title":"Epidemiological profile of reported tuberculosis in Tennessee, 2001","author":"Tennessee Department of Health","year":"2001"},{"key":"2026032101000126500_bib32","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/SMJ.0b013e3181611c9f","article-title":"Risk-based screening for latent tuberculosis infection","volume":"101","author":"Haley","year":"2008","journal-title":"South Med J"},{"key":"2026032101000126500_bib33","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/clinids\/17.6.968","article-title":"The tuberculin skin test","volume":"17","author":"Huebner","year":"1993","journal-title":"Clin Infect Dis"},{"key":"2026032101000126500_bib34","article-title":"A clinician\u2019s guide to tuberculosis","author":"Iseman","year":"2000"},{"key":"2026032101000126500_bib35","author":"Cain"},{"key":"2026032101000126500_bib36","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1164\/ajrccm\/145.1.36","article-title":"A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong","volume":"145","author":"Hong Kong Chest Service\/Tuberculosis Research Centre, Madras\/British Medical Research Council","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"2026032101000126500_bib37","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1164\/ajrccm.154.5.8912767","article-title":"Rifampin preventive therapy for tuberculosis in Boston\u2019s homeless","volume":"154","author":"Polesky","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101000126500_bib38","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1164\/rccm.200405-584PP","article-title":"Considering the role of four months of rifampin in the treatment of latent tuberculosis infection","volume":"170","author":"Reichman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101000126500_bib39","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1164\/ajrccm.155.5.9154885","article-title":"Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents","volume":"155","author":"Villarino","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101000126500_bib40","first-page":"1352","article-title":"Preventive chemotherapy. Where has it got us? Where to go next?","volume":"12","author":"Landry","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026032101000126500_bib41","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.5588\/ijtld.10.0518","article-title":"Missed opportunities to prevent tuberculosis in foreign-born persons, Connecticut, 2005\u20132008","volume":"15","author":"Guh","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026032101000126500_bib42","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1164\/rccm.201101-0181OC","article-title":"Priorities for screening and treatment of latent tuberculosis infection in the United States","volume":"184","author":"Linas","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101000126500_bib43"},{"key":"2026032101000126500_bib44","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s10903-010-9338-4","article-title":"Tuberculosis knowledge, attitudes, and beliefs in foreign-born and US-born patients with latent tuberculosis infection","volume":"12","author":"Colson","journal-title":"J Immigr Minor Health"},{"key":"2026032101000126500_bib45","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1164\/rccm.200510-1667OC","article-title":"Predicting non-completion of treatment for latent tuberculous infection: a prospective survey","volume":"174","author":"Shieh","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101000126500_bib46","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1164\/ajrccm.159.1.9807020","article-title":"A tuberculin screening and isoniazid preventive therapy program in an inner-city population","volume":"159","author":"Bock","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101000126500_bib47","first-page":"1296","article-title":"Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons","volume":"127","author":"Lobato","year":"2005","journal-title":"Chest"},{"key":"2026032101000126500_bib48","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1086\/520453","article-title":"Community-wide implementation of targeted testing for and treatment of latent tuberculosis infection","volume":"29","author":"Nolan","year":"1999","journal-title":"Clin Infect Dis"},{"key":"2026032101000126500_bib49","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1001\/archinte.160.5.697","article-title":"Adherence to isoniazid prophylaxis in the homeless: a randomized controlled trial","volume":"160","author":"Tulsky","year":"2000","journal-title":"Arch Intern Med"},{"key":"2026032101000126500_bib50","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2105\/AJPH.88.2.223","article-title":"Screening for tuberculosis in jail and clinic follow-up after release","volume":"88","author":"Tulsky","year":"1998","journal-title":"Am J Public Health"},{"key":"2026032101000126500_bib51","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1001\/archinte.162.9.1044","article-title":"Randomized controlled trial of interventions to improve follow-up for latent tuberculosis infection after release from jail","volume":"162","author":"White","year":"2002","journal-title":"Arch Intern Med"},{"key":"2026032101000126500_bib52","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.amepre.2005.06.014","article-title":"Incidence of TB in inmates with latent TB infection: 5-year follow-up","volume":"29","author":"White","year":"2005","journal-title":"Am J Prev Med"},{"key":"2026032101000126500_bib53","author":"Sterling"},{"key":"2026032101000126500_bib54","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1378\/chest.130.6.1712","article-title":"Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin","volume":"130","author":"Lardizabal","year":"2006","journal-title":"Chest"},{"key":"2026032101000126500_bib55","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1164\/rccm.200404-478OC","article-title":"Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months","volume":"170","author":"Menzies","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101000126500_bib56","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1001\/archinte.166.17.1863","article-title":"Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study","volume":"166","author":"Page","year":"2006","journal-title":"Arch Intern Med"},{"key":"2026032101000126500_bib57","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1086\/647944","article-title":"4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity","volume":"49","author":"Ziakas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2026032101000126500_bib58","author":"Charles"},{"key":"2026032101000126500_bib59","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jinf.2006.04.010","article-title":"Predictors of failure to complete treatment for latent tuberculosis infection","volume":"54","author":"Parsyan","year":"2007","journal-title":"J Infect"},{"key":"2026032101000126500_bib60","article-title":"Tuberculosis evidence-statement: screening","author":"Marks"},{"key":"2026032101000126500_bib61","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMsa043194","article-title":"Domestic returns from investment in the control of tuberculosis in other countries","volume":"353","author":"Schwartzman","year":"2005","journal-title":"N Engl J Med"},{"key":"2026032101000126500_bib62","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/thx.2009.125054","article-title":"Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB","volume":"65","author":"Aspler","year":"2010","journal-title":"Thorax"},{"key":"2026032101000126500_bib63","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1164\/rccm.200901-0153OC","article-title":"Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection","volume":"179","author":"Holland","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101000126500_bib64","first-page":"1","article-title":"Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection - United States","volume":"59","author":"Mazurek","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"2026032101000126500_bib65","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/1472-6963-11-247","article-title":"Systematic review of cost and cost-effectiveness of different TB-screening strategies","volume":"11","author":"Nienhaus","year":"2011","journal-title":"BMC Health Serv Res"},{"key":"2026032101000126500_bib66","first-page":"16","article-title":"Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis","volume":"11","author":"Oxlade","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026032101000126500_bib67"},{"key":"2026032101000126500_bib68","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1164\/rccm.200701-057OC","article-title":"Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999\u20132000","volume":"177","author":"Bennett","year":"2008","journal-title":"Am J Respir Crit Care Med"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/186\/3\/273\/67246931\/ajrccm_186_3_273.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/186\/3\/273\/67246931\/ajrccm_186_3_273.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T05:00:16Z","timestamp":1774069216000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/186\/3\/273\/8507614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,1]]},"references-count":68,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2012,8,1]]},"published-print":{"date-parts":[[2012,8,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201111-2076oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,8]]},"published":{"date-parts":[[2012,8,1]]}}}